-
Sinovac COVID-19 Vaccine Trial Halted In Brazil Over Adverse Event
Tuesday, November 10, 2020 - 4:31am | 451Read More...Brazilian health regulator has decided to halt clinical trials of a frontrunning Chinese vaccine following a “severe adverse event” observed in a participant, Bloomberg reported Monday. CoronaVac, a vaccine candidate developed through joint efforts by Chinese biopharma...
-
Sinovac Plans To Expand COVID-19 Vaccine Trials To Children And Adolescents
Thursday, September 17, 2020 - 3:15am | 446Read More...Sinovac Biotech has plans to expand the clinical trial of its COVID-19 vaccine trial to children and adolescents later this month. What Happened: The Chinese vaccine maker hopes to carry out the study on 552 healthy participants ranging between the ages of three and 17, according to information the...
-
Sinovac Makes Headway In Coronavirus Vaccine Race With Positive Preliminary Phase 1/2 Results
Monday, June 15, 2020 - 8:55am | 430Read More...Chinese biopharma Sinovac Biotech, which is one of 10 companies doing human testing of a vaccine candidate for SARS-CoV-2, the virus that causes COVID-19, announced positive preliminary data Monday from Phase 1/2 clinical trials. What Happened: The company said its vaccine candidate...
-
Sinovac Biotech Ltd. Stock Surged Amid 'Hostile Takeover'
Thursday, February 4, 2016 - 10:32am | 348Read More...Shares of Sinovac Biotech Ltd. (NASDAQ: SVA) were trading up more than 13 percent in Thursday's pre-market session after the company announced it received a non-binding proposal letter from a consortium of investors to acquire the company for $7.00 per share. The consortium includes PKU V-...
-
Sinovac Biotech Confirms Acquisition Offer, Shares Spike
Monday, February 1, 2016 - 12:23pm | 161Read More...Shares of Sinovac Biotech Ltd. (NASDAQ: SVA), a China-based biopharmaceutical company that focuses on vaccines that protect against human infectious diseases, spiked higher by more than 18 percent at $5.94 on Monday. Sinovac Biotech announced earlier in the day that the Board of Directors...
-
Exclusive: Chinese Biopharma Sinovac 'Can't See Any Reason' EV71 Vaccine Candidate Won't Get Approval
Thursday, September 24, 2015 - 3:47pm | 4360Read More...This interview was conducted by Ezra Marbach. Last week I met with management of Chinese small-cap Sinovac Biotech Ltd. (NASDAQ: SVA) while they were in New York for the Morgan Stanley Healthcare Conference. We spoke for almost an hour. Here’s the conversation in full (lightly edited):...
-
Benzinga's Upgrades for May 15, 2013
Wednesday, May 15, 2013 - 2:15pm | 11Read More...Check out these stock upgrades for this date of Wednesday, May 15.
-
Piper Jaffray Lowers Sinovac Biotech 12-Month PT
Monday, October 25, 2010 - 7:59am | 114Read More...Sinovac Biotech, Ltd. (NASDAQ: SVA) lowered its full year revenue guidance from $60-67m to $40-45m, which was somewhat expected (notes 09/30 and 10/22) but should result in SVA share weakness nonetheless, Piper Jaffray reports. “We think that management should have a greater level of confidence (...
